Novolog (NVLG) Q2 2026 earnings summary

Executive summary

• Q2 2026 revenue grew 2.3% year-over-year to ₪451.9M, with H1 2026 revenue at ₪957.7M, up 1% year-over-year.

• Net income for Q2 2026 was ₪0.5M, with Adjusted EBITDA at ₪31.4M; H1 2026 net income was ₪0.7M and Adjusted EBITDA ₪55.8M.

• For the six months ended June 30, 2026, revenue was ₪1,805M, gross profit reached ₪137.5M, and Adjusted EBITDA was ₪128.8M.

• The company completed the sale of non-core assets, continued streamlining operations, and underwent major management changes.

• Operates across three profitable segments: logistics, healthcare, and digital health.

Financial highlights

• Q2 2026 gross profit was ₪36.3M, up 2.1% year-over-year; H1 2026 gross profit was ₪137.5M.

• Gross margin improved to 7.6% from 6.7% year-over-year.

• Operating expenses decreased due to efficiency measures.

• Cash and equivalents at period end were ₪121.8M.

• Cash flow from operations was negative ₪726 thousand, compared to positive ₪17.8M in the prior year.

Outlook and guidance

• Focus on operational efficiency, innovation, and customer-centric growth.

• Strategic investments in organic growth, acquisitions, and portfolio optimization to support long-term expansion.

• Expected gain of ₪6.5M from the sale of Salus, pending completion.